Drug Profile
BI 690517
Alternative Names: BI-690517; C 14Latest Information Update: 09 Nov 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Renal failure
- No development reported Diabetic nephropathies
Most Recent Events
- 03 Nov 2023 Efficacy and adverse events data from a phase II trial in Renal failure released by Boehringer Ingelheim
- 03 Nov 2023 Boehringer Ingelheim plans the phase III EASi-KIDNEYTM trial for Renal failure (Combination therapy) in 2024
- 10 Jul 2023 Boehringer Ingelheim completes a phase-II trial in Renal failure (Monotherapy, Combination therapy) in Turkey, Switzerland, Sweden, Spain, South Africa, Portugal, Poland, Philippines, Norway, Mexico, Malaysia, South Korea, Japan, Italy, India, Hungary, Hong Kong, Greece, Germany, Denmark, Czech Republic, China, Bulgaria, Canada, Brazil, Belgium, Australia, Argentina, Finland and USA (PO) (NCT05182840)